Use of D‐dimer in oral anticoagulation therapy

Zhang, L.; Long, Yanli; Xiao, Han; Yang, Jun; Toulon, Pierre; Zhang, Z.

doi:10.1111/ijlh.12864

Cited by 43 publications

(42 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated D‐dimer was always associated with unfavorable events 20,21 . Previously, the lack of specificity has been regarded as a disadvantage of D‐dimer 7 . However, low specificity has been transformed into one of its advantages in the evaluation of prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, early and effective predictors of clinical outcomes are urgent needed for risk stratification of Covid‐19 patients. D‐dimer originates from the formation and lysis of cross‐linked fibrin and reflects activation of coagulation and fibrinolysis 7 . It has been reported that Covid‐19 was associated with hemostatic abnormalities, and markedly elevated D‐dimer levels were observed in those nonsurvivors 8 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19

Zhang

Yan

Fan

et al. 2020

Journal of Thrombosis and Haemostasis

Self Cite

1,177

1,091

View full text Add to dashboard Cite

Background The outbreak of the coronavirus disease 2019 (Covid‐19) has shown a global spreading trend. Early and effective predictors of clinical outcomes are urgently needed to improve management of Covid‐19 patients. Objective The aim of the present study was to evaluate whether elevated D‐dimer levels could predict mortality in patients with Covid‐19. Methods Patients with laboratory confirmed Covid‐19 were retrospective enrolled in Wuhan Asia General Hospital from January 12, 2020, to March 15, 2020. D‐dimer levels on admission and death events were collected to calculate the optimum cutoff using receiver operating characteristic curves. According to the cutoff, the subjects were divided into two groups. Then the in‐hospital mortality between two groups were compared to assess the predictive value of D‐dimer level. Results A total of 343 eligible patients were enrolled in the study. The optimum cutoff value of D‐dimer to predict in‐hospital mortality was 2.0 µg/mL with a sensitivity of 92.3% and a specificity of 83.3%. There were 67 patients with D‐dimer ≥2.0 µg/mL, and 267 patients with D‐dimer <2.0 µg/mL on admission. 13 deaths occurred during hospitalization. Patients with D‐dimer levels ≥2.0 µg/mL had a higher incidence of mortality when comparing with those who with D‐dimer levels <2.0 µg/mL (12/67 vs 1/267, P < .001; hazard ratio, 51.5; 95% confidence interval, 12.9‐206.7). Conclusions D‐dimer on admission greater than 2.0 µg/mL (fourfold increase) could effectively predict in‐hospital mortality in patients with Covid‐19, which indicated D‐dimer could be an early and helpful marker to improve management of Covid‐19 patients. (Chinese Clinical Trial Registry: ChiCTR2000031428).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19

Zhang

Yan

Fan

et al. 2020

Journal of Thrombosis and Haemostasis

Self Cite

1,177

1,091

View full text Add to dashboard Cite

show abstract

“…D-dimer levels as marker of hypercoagulable state and intravascular thrombosis are frequently increased in clinical settings including severe infections, sepsis, deep vein thrombosis, and pulmonary embolism [ 38 , 39 ]. Elevated levels of D-dimer and its association with poor clinical outcomes were reported in patients with COVID-19 in a recent study and a D-dimer level of >2.0 µg/mL on admission (fourfold increase) effectively predicted inhospital mortality in patients with COVID-19 [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Association between renin–angiotensin–aldosterone system inhibitor treatment, neutrophil–lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study

et al. 2020

View full text Add to dashboard Cite

The aim of this study was to investigate the possible relationship between worse clinical outcomes and the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in hospitalized COVID-19 patients. A total of 247 adult patients (154 males, 93 females; mean age: 51.3 ± 14.2 years) hospitalized for COVID-19 as confirmed by polymerase chain reaction (PCR) were retrospectively reviewed. Demographic and clinical characteristics and laboratory parameters were analyzed using various statistical modeling. Primary outcomes were defined as the need for intensive care unit (ICU), mechanical ventilation, or occurrence of death. Of the patients, 48 were treated in the ICU with a high flow oxygen/noninvasive mechanical ventilation (NIMV, n = 12) or mechanical ventilation ( n = 36). Median length of ICU stay was 13 (range, 7–18) days. Mortality was seen in four of the ICU patients. Other patients were followed in the COVID-19 services for a median of 7 days. There was no significant correlation between the primary outcomes and use of ACEIs/ARBs (frequentist OR = 0.82, 95% confidence interval (CI) 0.29–2.34, p = 0.715 and Bayesian posterior median OR = 0.80, 95% CI 0.31–2.02) and presence of hypertension (frequentist OR = 1.23, 95% CI 0.52–2.92, p = 0.631 and Bayesian posterior median OR = 1.25, 95% CI 0.58–2.60). Neutrophil-to-lymphocyte ratio (NLR) and D-dimer levels were strongly associated with primary outcomes. In conclusion, the presence of hypertension and use of ACEIs/ARBs were not significantly associated with poor primary clinical outcomes; however, NLR and D-dimer levels were strong predictors of clinical worsening.

show abstract

“…The challenge was to find effective predictors of COVID-19 critical disease and death in order to identify critical patients early. Elevation of D-dimer indicated an hypercoagulable state in patient with Covid-19 and reflects activation of coagulation and fibrinolysis [ 3 ]. Recent literature data show that D-dimer values are frequently enhanced in non-survivor patients with COVID-19 [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Elevated levels of D-dimer in patients with COVID-19: prognosis value

Oualim¹,

Abdeladim²,

Ouarradi³

et al. 2020

Pan Afr Med J

View full text Add to dashboard Cite

Introduction: coronavirus disease is now a global pandemic due to rapid human-to-human transmission. It can cause mild to fatal respiratory, cardiovascular, and neurological diseases. We aimed to find out whether elevated D-dimer levels are a predictor of the bad progression of COVID-19 to help reducing the mortality. Methods: the data of COVID-19 patients from March 21, 2020 to April 24, 2020 were retrieved from the Cheick Khalifa Hospital database. We used the receiver operating characteristic (ROC) curve to get the optimum cutoff value of D-dimer levels on admission and after 5 days. We used these cutoffs to divide patients into two groups and compare the in-hospital mortality between them to assess the prognosis value of D-dimer levels. Results: the data of COVID-19 patients from March 21, 2020 to April 24, 2020 were retrieved from the Cheick Khalifa Hospital database. We used the receiver operating characteristic (ROC) curve to get the optimum cutoff value of D-dimer levels on admission and after 5 days. We used these cutoffs to divide patients into two groups and compare the in-hospital mortality between them to assess the prognosis value of D-dimer levels. 89 patients were included in this study, of whom 79 were discharged and 10 died in hospital. The optimum cutoff value to predict mortality in patient using D-dimer levels on admission was 668 ng/ml (sensitivity 90%, specificity 63.3%, Areas under the ROC curve 0,775). As for D-dimer levels on day 5, it was 1360 ng/ml (sensitivity 100%, specificity 88,6%, Areas under the ROC curve 0.946). The group with D-dimer levels on day 5 > 1360 ng/ml (19 patients) had a worst evolution and a higher incidence of mortality compared to the group with D-dimer < 1360 ng/ml (69 patients) (10/19 vs 0/69, P = 0,0002). Conclusion: D-dimer greater than 1360 ng/ml on day 5 could help clinicians identify patients with poor prognosis at an early stage of COVID-19.

show abstract

Use of D‐dimer in oral anticoagulation therapy

Cited by 43 publications

References 61 publications

D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19

D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19

Association between renin–angiotensin–aldosterone system inhibitor treatment, neutrophil–lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study

Elevated levels of D-dimer in patients with COVID-19: prognosis value

Contact Info

Product

Resources

About